FDA grants approval to Revolution Medicines' Rasonque for pancreatic cancer
read at Endpoints ↗ApprovalPositive
The U.S. Food and Drug Administration has approved Rasonque, a new therapy from Revolution Medicines, for the treatment of pancreatic cancer.
The decision follows data that showed the drug nearly doubled patient outcomes in an earlier trial, generating strong enthusiasm among oncologists.
The approval marks a significant milestone for a disease with limited options and could broaden treatment options for patients with advanced disease.
Industry observers note that the success may spur further investment in targeted therapies for pancreatic cancer.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Landmark approval for pancreatic cancer; Reactions to Lilly’s Phase 1 secrecy; and more”
read at Endpoints ↗84 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that